Backed by Norwest.
About the role
The Director, Clinical Development Research Scientist will report to the Senior Vice President, Clinical Development and serve as a key clinical and scientific leader advancing Avalyn’s IPF/ILD clinical development programs. This individual will provide therapeutic-area expertise and strategic leadership across the development lifecycle, from program and study strategy through protocol design, clinical execution, data interpretation, regulatory interactions, and development planning. Found on 1752vc Careers, the job board for startup and VC roles.
What they're looking for
- Advanced clinical or scientific degree (e.g., DNP, APRN, MD, PhD or equivalent) with significant clinical research, clinical development, or relevant therapeutic-area experience
- 7–10+ years of experience in clinical research, clinical development, drug development, or a related field, including meaningful sponsor-side experience
- Deep expertise in IPF, ILD, or pulmonary medicine, , with a strong understanding of the treatment landscape and unmet patient needs
- Demonstrated experience leading or contributing to Phase 2 and/or Phase 3 clinical trials, including strong experience in protocol development, clinical trial strategy, safety monitoring, and risk mitigation
- Demonstrated ability to interpret clinical safety and efficacy data and translate findings into evidence-based, program-level development decisions
- Experience contributing to clinical development strategy across multiple studies and/or development stages, with the ability to connect study-level decisions to broader program, portfolio, and product objectives
More about this role
Avalyn aims to transform the treatment paradigm for pulmonary fibrosis and other serious, rare respiratory diseases. The company is advancing optimized inhaled formulations of established antifibrotic medicines designed to deliver drug directly to the lungs, enhance local efficacy, and reduce systemic side effects. Avalyn’s AP01 program is an optimized inhaled formulation of pirfenidone currently being evaluated in MIST, a global Phase 2b clinical trial in patients with progressive pulmonary fibrosis (PPF). AP01 has demonstrated encouraging safety and clinical activity across Phase 1b and an ongoing, multi-year open-label extension trial, with long-term data supporting the potential to preserve lung function while improving tolerability relative to historical oral pirfenidone. Avalyn’s AP02 program is an optimized inhaled formulation of nintedanib currently being evaluated in AURA, a global Phase 2 clinical trial in patients with idiopathic pulmonary fibrosis (IPF). Avalyn is also advancing AP03, an inhaled fixed-dose combination of pirfenidone and nintedanib, designed to deliver multiple antifibrotic mechanisms through a single lung-targeted platform. By leveraging its...
Browse similar: AI jobs · AI startup jobs · Startup jobs · Remote jobs